Explore the Agenda

Regulatory Bootcamp

Understanding Regulatory Landscapes to Navigate Approvals & Accelerate Global Cell Therapy Development

9:30 am Roundtable Discussion: Navigating MHRA Guidelines for CAR-T & TCR-T Therapies

  • Discuss best practices for engaging with the MHRA to clarify expectations
  • Outline approaches to documentation, testing, and compliance that support smooth regulatory interactions

10:00 am Navigating Asia–EMA Regulatory Pathways to Accelerate Global Development

Director, Regulatory Policy & Intelligence, AstraZeneca
  • Compare regulatory frameworks, approval pathways, and clinical trial requirements across key Asian markets and the EMA
  • Identify opportunities to streamline global development by leveraging Asia’s evolving regulatory landscape
  • Highlight emerging opportunities for biotechs to expand into Asian markets through collaborative or parallel regulatory approaches

Partnerships & Investment Bootcamp

Seizing Opportunities for Funding & Data to Progress in the Current Financial Climate

9:30 am Navigating Ethics Approval for Investigator Initiated Trial Set-Up in China for Early Human Data

Chief Scientific Officer, IASO Therapeutics
  • Discuss the step-by-step process for obtaining ethics approval in China’s regulatory environment
  • Highlight practical lessons from setting up IITs with local investigators to accelerate trial initiation
  • Share how early human data from Chinese IITs can de-risk development and build credibility with global investors and partners

10:00 am Understanding How Clusters Accelerate Grants & Growth in Europe

Professor & Head of Haematology Department, University Hospital Dresden, Saxocell Cluster4Future
  • Explain how European and national consortia and cluster models connect biotechs with academic and industry partners
  • Highlight the advantage of shared infrastructure and credibility in winning non-dilutive strategic national grants

10:30 am Morning Networking Break

Unlocking Market Access with Modernised Regulatory Pathways

11:00 am Panel Discussion: Current Efforts to Spearhead Regulatory Modernisation & Acceptance of Novel CGT Technologies

Scientific, Car T Cell Therapy Centre & cGMP Cell Therapy Unit Project Officer, Tata Memorial Centre
Group Leader, Heidelberg University Hospital
Director, Regulatory Policy & Intelligence, AstraZeneca
  • Share how regulators in Europe, the US, and Asia are adapting frameworks to keep pace with emerging cell and gene therapy technologies
  • Highlight initiatives that foster earlier and more constructive engagement
  • Understand how modernisation efforts can accelerate approvals, support broader adoption, and make CGTs more commercially viable

12:00 pm Planning Early for European Market Entry: Navigating Regulatory & Access Differences Between the US & EU

Executive Director & Head of Market Development & New Product Planning, Cabaletta Bio
  • Highlight the importance of early strategic planning for US biotechs expanding into Europe to avoid rushed launches and regulatory setbacks
  • Compare FDA prerequisites and EMA expectations to identify critical divergences that can impact timelines and trial readiness
  • Discuss market access procedures and lessons learned from companies like Cabaletta on how to successfully prepare for European entry

Strengthening Biotech, Pharma, & Academic Collaborations to Accelerate Growth & Reduce Risk

11:00 am Panel Discussion: Building Stronger Bridges Between Biotechs, Pharma & Investors

Chief Scientific Officer, Esobiotec
Chief Scientific Officer, Lift Biosciences
Chief Executive Officer, Edity Therapeutics
Senior Director, Search & Evaluation R&I, AstraZeneca
  • Share how biotechs can present data and strategy in ways that help investors and pharma make faster, more confident decisions, reducing risk on both sides
  • Highlight how pharma and investors can communicate expectations more clearly ensuring companies design studies and pipelines that are partner-ready

12:00 pm Roundtable Discussion: Expanding Global Access to CAR-T Therapy Through Academic & Industry Partnership Models

  • Compare academic–academic and academic–industry collaboration models to expand manufacturing capacity and reduce therapy costs
  • Share lessons on commercialising CAR-Ts at accessible pricing and leveraging international partnerships to improve patient access and reduce waitlist mortality

12:30 pm Lunch & Networking Break

Advancing Cell Therapy Reach via Streamlined Patient Access Frameworks

1:30 pm Leveraging Hospital Exemption & Compassionate Use to Improve Patient Access Under Evolving EU Legislations

Head of Immunotherapy Platform, Hospital Clinic of Barcelona
  • Discuss how hospital exemptions and compassionate use frameworks operate across Europe and their role in bridging access gaps
  • Highlight the implications of ongoing legislative reviews on developer responsibilities, regulatory oversight, and safety standards

2:00 pm Roundtable Discussion: Navigating Access & Reimbursement Challenges in Europe

  • Discuss the major differences in reimbursement pathways between the US and European markets
  • Examine how pricing, evidence generation, and value demonstration impact payer negotiations and long-term sustainability of cell therapies
  • Discuss practical steps developers can take early in clinical and regulatory planning to prepare for country-specific reimbursement challenges and accelerate access post-approval

Strengthening Biotech, Pharma, & Investor Collaborations to Accelerate Growth & Reduce Risk

1:30 pm Strategic Matchmaking Roundtable Session: Connecting Innovators with Pharma, Investors, & C-Level Insights to Refine Partnership Readiness

Chief Scientific Officer, Esobiotec
Senior Director, Search & Evaluation R&I, AstraZeneca
  • Rotate through the tables to learn from Pharma and C-level executives with partnership experience, and gain practical insights to shape your future strategy

2:30 pm End of Strategic Bootcamp Days

2:45 pm C-Level Think Tank

President, Science & Technology, Cabaletta Bio
Founder, Quell Therapeutics

A closed door discussion uniting top C-level executives from biotech and senior executives from pharma to discuss the most pressing challenges and advancements shaping the CAR-TCR field in Europe. This year’s Think Tank explores Tregs in autoimmune disease to understand how they can be leveraged as therapies and their significance when other effector cell therapies are used.

Invite Only

Co Chairs: